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Abstract
BACKGROUND—Verification of surgical staging has received little attention in clinical 
oncology trials for both children and adults. Central surgical review in a study of malignant 
pediatric germ cell tumors provided an opportunity to assess the impact of this process.
METHODS—Children’s Oncology Group study AGCT0132 data submission at study entry 
required operative note, surgical checklist, pathology and imaging reports. Central surgical review 
during the study included assessment for completeness of submitted data and confirmation of 
assigned stage. Review resulted in one of three conclusions: assigned status confirmed, assignment 
withheld pending review of additional information requested, or institutional assignment of stage 
disputed with reasons for recommended stage assignment explained. Changes in stage assignment 
based on central surgical review were left at the discretion of the enrolling institution.
RESULTS—206 patients underwent central review. Failure to submit required data elements or 
need for clarification was noted in 40%. Disagreement with stage assignment occurred in 10%; the 
highest rate of discordance was in ovarian tumors submitted as stage I (34%). 17 of 21 discordant 
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patients were reassigned to the stage recommended by central review. 4 patients with ovarian 
tumors not meeting central review criteria for Stage I remained in that stratum by institutional 
decision. Two-year event free survival (EFS) in Stage I ovarian tumor patients was 25% (1/4) for 
discordant patients compared to 57% (9/21) in patients who met Stage I criteria by central review.
CONCLUSIONS—Central review of stage assignment by a dedicated study surgeon improved 
collection of complete data and assignment of correct tumor stage at study entry, and allowed for 
prompt initiation of chemotherapy in patients determined not to have Stage I disease.
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Introduction
Oncology clinical trials require careful and accurate data collection for reliable 
interpretation. Although the details for administration and monitoring of chemotherapy and 
radiation are specifically defined and recorded, the surgical aspects of cancer treatment have 
been less rigorously evaluated. The concept of quality assessment in surgical oncology has 
had limited attention. In most studies, surgical data have been assumed to be consistent or 
reviewed only in retrospect. It is difficult to define and monitor the technical details that may 
be important for a given procedure. This has the most impact when adjuvant therapy is stage 
dependent for a planned protocol, and surgical details relevant to stage assignment are not 
scrutinized.1, 2
Most studies of pediatric cancer require multi-institutional trials carried out over several 
years and are particularly challenging. Available studies of surgical factors in pediatric solid 
tumors have revealed frequent lack of compliance with existing guidelines which may have 
an impact on stage assignment and outcome. 3–8 In some studies, retrospective analysis of 
the required elements of the surgical staging procedure has permitted evidence based 
modification for the surgical approach to the tumor.5, 9 The goal of accurate and appropriate 
surgical staging may be accomplished by the timely confirmation and review of complete 
data collection. Real time review of operative information while a study is ongoing can 
provide an opportunity for dialogue with the individual centers to clarify details in the 
operative notes, capture missing data, confirm appropriate staging assignment, and allow 
quality assessment and education.
METHODS
The Children’s Oncology Group (COG) protocol AGCT 0132 was designed to investigate a 
surveillance strategy after complete tumor excision for low risk gonadal tumors, and reduced 
chemotherapy for intermediate risk pediatric extra cranial malignant germ cell tumors 
(MGCT). The low risk (LR) stratum included Stage I tumors of the testis and ovary. Low 
risk tumors were treated with surgical resection and surveillance only, and compressed 
platinum based chemotherapy (PEB) was reserved for patients with persistently elevated 
markers or evidence of relapse. The intermediate risk (IR) stratum included Stage I-III 
extragonadal tumors, Stage II-IV testicular tumors, and Stage II-III ovarian tumors. 
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Intermediate risk tumors were treated with resection and compressed platinum based therapy 
at diagnosis. IRB approval was obtained at all participating centers. Required malignant 
histology included at least one of the following: yolk sac, choriocarcinoma, or embryonal 
carcinoma. Patients with pure germinoma, pure immature teratoma and those with additional 
somatic malignancies were excluded.
Required data at enrollment included submission of “on study” form, operative note, 
surgical checklist, institutional pathology report, and reports of imaging studies for 
evaluation of metastasis at diagnosis. Central review of pathology was also done. 
Assignment to the surveillance strategy for Stage I testis and ovary patients required strict 
adherence to COG surgical guidelines to ensure accurate assessment.
Data monitoring during the study revealed a higher than expected event rate in the low risk 
stratum and enrollment was temporarily suspended. This was due to a miscalculation in the 
failure model that predicted a uniform rate of relapse events over the first three years, when 
most relapses occurred within one year. The low risk arm was reopened with increased 
monitoring to include rapid central surgical review of the data by a COG study surgeon 
within 72 hours of enrollment. Those patients submitted for enrollment as intermediate risk 
(Stage I extragonadal, Stage II and III gonadal and extragonadal tumors, Stage IV testicular 
tumors) also underwent central surgical review while the study remained open, but without 
the 72 hour deadline (real time review). Data were submitted and catalogued through the 
electronic remote data entry system (eRDS) and study surgeons were sent electronic 
notification that data were available for review. Review of the operative note, pathology 
report, surgical checklist and imaging findings was undertaken to confirm stage status for all 
patients. Any missing data forms or discrepancies in submitted data generated a request by 
the study surgeon to the enrolling institution for additional information and/or clarification. 
Central stage assignment was completed after requested information was submitted or 
clarified by the enrolling institution. If the study surgeon concluded that the patient should 
have a different stage assignment, this was communicated to the institutional investigator 
and action on the evaluation was at the discretion of the enrolling institution.
A retrospective analysis of those patients undergoing central surgical review was done. The 
number of patients in whom additional data was requested to assess status was determined. 
The number and final stage assignment for those patients who did not meet central review 
criteria for their enrolled stage was also determined.
Event free survival (EFS) was defined as the time from enrollment to disease progression, 
death from any cause, diagnosis of a second malignant neoplasm, or last follow-up 
whichever occurred first. Patients who did not experience disease progression, death or 
second malignancy were consider event-free at last contact; all other patients were 
considered to have experienced an event. EFS as a function of time since enrollment was 
estimated by the method of Kaplan and Meier.10 Event free survival was examined for those 
who were concordant and discordant with central review. Because a small number of 
patients was considered discordant, the calculation of meaningful statistical tests was 
prevented.
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RESULTS
Of the 286 patients on the protocol, 206 were enrolled after central review was instituted. 
The number of patients in whom there was discordance between institutional stage 
assignment and central review of stage is shown in Table 1. Central review of the assigned 
stage was confirmed in 90% of patients overall ranging from 66% in Stage I ovarian tumors 
to 97% in Stage I testicular tumors. Disagreement in stage assignment was noted in all 
categories. The highest rate of discordance was in stage I ovarian tumors. Seven of 21 (34%) 
eligible patients with Stage I ovarian tumors were under-staged due to incomplete staging or 
failure to meet stage definition. Although 3 of 7 had their stage at enrollment changed to a 
higher stage as recommended by central review, 4 remained in the low risk stratum at the 
discretion of the enrolling institution. Event free survival for the patients with Stage I 
ovarian tumors was 57% (12/21) in those who were concordant by central review and 25% 
(1/ 4) in those who did not meet criteria for Stage I by central review. All other patients in 
whom there was discordance of stage assignment after central review were changed to the 
recommended stage and received protocol chemotherapy as appropriate for the revised stage. 
Additional information or requests for clarification were noted in 40% of patients overall 
with a range of 17–52% by stage. The information requests included need for submission of 
one of the required forms and/or clarification of inconsistencies regarding interpretation of 
findings in the operative, pathology or imaging reports. Missing data for ovarian tumors 
were most often the reports of peritoneal cytology or imaging findings. Missing data for 
testis and extragonadal tumors were most often imaging results.
Specialty of operating surgeon was examined for ovarian primary tumors and confirmed the 
variety of surgical providers for this patient population. For the 99 patients in which 
specialty of the operating surgeon could be determined, 71 were pediatric surgeons, 14 were 
gynecologic oncologists, 9 were gynecologists and 3 cases were done by 2 specialists 
(pediatric surgeon/gynecologic oncologist, general surgeon/gynecologic oncologist, general 
surgeon/gynecologist).
Discussion
Anatomical staging is the traditional basis for treatment and prediction of prognosis for all 
solid tumors. Although anatomic constraints during an individual operation preclude a fixed 
surgical approach to every patient, there are many components of a staging procedure that 
may be objectively categorized. Increasing knowledge based on patient characteristics and 
tumor biology has led to modified and more complex risk-adapted strategies. Although 
details for chemotherapy and radiation therapy are quite specific and carefully monitored in 
most protocols, compliance with guidelines for surgery has received limited attention. 
Anatomic and procedural factors that impact risk assignment are understudied. This is 
particularly problematic in pediatric tumors since the incidence is quite low and each 
institution will contribute only a small number of patients to each protocol. In addition, the 
child may be operated on by surgical specialists with training in a variety of pediatric and 
adult disciplines, and there is no shared mechanism for education regarding staging 
procedures across these specialties. Retrospective review of compliance with surgical 
guidelines in several pediatric solid tumor studies revealed compliance of 84% in a study of 
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neuroblastoma,9 3% in a study of ovarian germ cell tumors,5 69% in testicular germ cell 
tumors,4 and 57% in paratesticular rhabdomyosarcoma8. This is particularly relevant when 
intensity of treatment depends on stage assignment. In a study of patients enrolled on the 
National Wilms Tumor Study 4, Shamberger et al3 demonstrated a 6-fold increase in relative 
risk for relapse in stage I patients in whom lymph nodes were not biopsied as expected for 
stage assignment. This discrepancy in risk was not seen in the higher stage patients who 
received more intensive chemotherapy. An interesting finding was also seen in a study of 
neuroblastoma.9 In this review of patients with localized neuroblastoma, patients without 
lymph node biopsy were separated into two categories: those in whom lymph nodes had 
been sought but none were found (22.8%) and those in whom lymph nodes were present but 
the surgeon chose not to biopsy. Survival was superior in those who had lymph nodes sought 
but not found, compared to those assumed to have normal nodes that were not biopsied. This 
finding also emphasizes the importance of documentation rather than assumption in stage 
assignment. For those children with Stages B/C tumors one year of age and older: 5year 
survival was 69% in those who had lymph nodes sought and 40% in those who did not. This 
study also reviewed the location and yield of lymph node biopsies to provide an objective 
recommendation for subsequent surgical guidelines. For each anatomic area of primary 
tumor, documentation of search for lymph nodes in specific locations, with biopsy of any 
nodes found, was required.
A review of surgical compliance in pediatric malignant ovarian germ cell tumors also 
demonstrated excellent outcome despite failure to follow traditional staging guidelines that 
were based on adult epithelial cancers. Based on the yield of each component of the staging 
procedure that was performed, new guidelines were proposed for malignant pediatric ovarian 
germ cell tumors.5 The observation that random biopsies of normal tissues for pediatric 
malignant ovarian germ cell staging has negligible yield has been further confirmed in a 
subsequent study of malignant pediatric ovarian tumors of varied histology.11 Both of these 
studies demonstrate the value of careful review of data in evaluating extensive guidelines 
based on tradition. The guidelines may be modified based on objective data to minimize 
surgical morbidity, while retaining those components of the surgical procedure that 
contribute useful staging information.
Germ cell tumors are rare and complex malignancies with multiple anatomic primary sites 
and histologies. Advances in chemotherapy have allowed successful treatment for the 
majority of these patients, but with significant toxicities and long-term effects. Surgical 
therapy also carries inherent risks and complications. In the previous pediatric intergroup 
study for malignant germ cell tumors, scrotal violation in testicular tumors was associated 
with a significant decrease in event-free survival.4 In the ovarian tumors, peritoneal cytology 
was recognized to be an important component of the staging procedure. Sixteen of 58 (28%) 
of specimens obtained in stage III ovarian patients revealed malignant cells. Five of 58 girls 
were recognized to be stage III by the peritoneal cytology findings alone and would 
otherwise have been mistakenly assigned to stage I.5 Surgical overtreatment and morbidity 
was seen in six girls who underwent total abdominal hysterectomy and bilateral salpingo-
oophorectomy that was not recommended by protocol and one had iliac artery injury from 
lymph node dissection.5 A retrospective study of post surgical surveillance for ovarian germ 
cell tumors from France noted an increase in tumor events in those patients who had 
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incomplete staging.12 In the current study, tumor events were also seen more frequently in 
those who did not meet central review criteria for Stage I surveillance.
An additional benefit of real time review was the opportunity for interaction with the 
enrolling institutions. Clarification of uncertainties and discrepancies in operative, imaging 
and pathologic data improved accuracy. Feedback on discordance with stage assignment 
provided an educational opportunity for the enrolling institutions. Lack of clarity in the 
description of details in staging information in the protocol was exposed and provided an 
opportunity to improve descriptions and definitions for future protocols. The ability to 
communicate electronically in a secure fashion demonstrated the feasibility of successful 
confirmation of complete data submission and review within a 72 hour time frame when 
needed.
As risk groups are defined that allow a reduction in chemotherapy for solid tumors based on 
surgical stage, it is imperative that the details of the anatomic information be assessed for 
accuracy, completeness and relevance. Acknowledgment that the surgical procedure has an 
impact on outcome is important in advancing the care of these patients. Many components 
of surgical staging procedures are based on tradition rather than evidence based. Analysis of 
surgical procedures requires complete data collection to allow critical appraisal of the 
relevant operative details. Incomplete information should not be assumed to be negative as 
seen with the findings from peritoneal cytology sampling in malignant ovarian germ cell 
tumors, and in the lymph node studies in Wilms tumor and neuroblastoma. The application 
of a real time review of the data submission at entry by a dedicated study surgeon in this 
study revealed questions or incomplete data submission in 41% of patients, and a 
discrepancy between institution and study surgeon stage assignment in 3–34% of patients. 
Data requests by the study surgeons allowed retrieval of complete information, and provided 
an opportunity to undertake a detailed analysis of the potential risk factors for relapse events 
related to the anatomic findings. Improved assignment of stage at study entry allowed timely 
chemotherapy for those patients recognized to be greater than stage I and allowed event rates 
to be more accurately calculated. The inclusion of real time surgical review of data in solid 
tumor protocols at all ages and in all tumor types should be encouraged to assist in achieving 
complete anatomic and staging information that is consistent and reliable. Proper assignment 
of tumor stage will lead to more accurate interpretation of treatment protocols and improved 
design of future trials.
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Table 1
Summary of real time review findings by stage with impact on stage assignment.
SITE
(# eligible
submitted as
listed stage with
review)
ADDITIONAL
INFORMATION
REQUESTED
TOTAL (%)
REVIEW
CONFIRMED
STAGE
TOTAL (%)
REVIEW SHOWED
HIGHER STAGE
AND STRATUM
ASSIGNED
CHANGED
TOTAL (% eligible)
REVIEW SHOWED
HIGHER STAGE BUT
STRATUM ASSIGNMENT
NOT CHANGED
TOTAL (% eligible)
LOW RISK
  STAGE I OVARY
    (21)
6/21 (29%) 14 /21 (66%) 3/21 (14%) 4/21 (19%)
  STAGE I TESTIS
    (60)
26/60 (43%) 58/60 (97%) 2/60 (3%) 0
INT RISK
STAGE II/III
OVARY
    (77)
40/77 (52%) 71/77 (92%) N/A N/A
STAGE II–IV
TESTIS
    (18)
5/18 (28%) 15/18 (83%) N/A N/A
STAGE I–II
EXTRAGONADAL
    (30)
5/30 (17%) 27/30 (90%) N/A N/A
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